Show Summary Details
Page of



Columba Quigley

and Paul Glare

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 17 September 2021

Chapter 14 discusses Hydromorphone (HM), also known as dihydromorphinone in the older literature, a semi-synthetic derivative of morphine with a long history of successful use as an opioid analgesic, having been developed in 1922 by Knoll and used for cancer pain since 1932. It is almost pharmacologically identical to morphine but has the advantages of high solubility in water and availability in a variety of dosage forms. HM is widely used for opioid rotation in cancer pain management, even though there is currently no evidence for any clinically significant differences between HM and morphine in terms of efficacy or tolerance. Uncertainty remains about the correct oral-to-parenteral ratio for HM, and the equipotency ratio between HM and other strong opioids.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.